Upstream Bio, INC 8-K filings

Upstream Bio reported second quarter 2026 financial results and business updates, highlighting progress in its verekitug development for severe inflammatory respiratory diseases and a cash runway through 2027.

Upstream Bio, Inc. announced the results of its 2026 Annual Meeting of Stockholders, confirming the election of two Class II directors and the ratification of PricewaterhouseCoopers LLP as its independent auditor.

Upstream Bio announced first quarter 2026 financial results, highlighting progress in its Phase 3 programs for severe asthma and CRSwNP, while adjusting its COPD trial enrollment.

Upstream Bio, Inc. has entered into a sales agreement with Leerink Partners LLC to potentially sell up to $150 million of its common stock through an at-the-market offering.

Upstream Bio announced its Phase 3 development strategy for verekitug in severe asthma and CRSwNP, alongside its fourth quarter and full year 2025 financial results.

Upstream Bio announced positive top-line results from its Phase 2 VALIANT clinical trial for verekitug in severe asthma, meeting its primary endpoint.

Upstream Bio announced positive top-line results from its Phase 2 VALIANT trial for verekitug in severe asthma, meeting its primary endpoint with significant reductions in exacerbation rates.

Upstream Bio announced positive top-line Phase 2 results for verekitug in CRSwNP, reported Q3 2025 financial results, and provided updates on its severe asthma and COPD trials.

Upstream Bio announced positive top-line results from its Phase 2 VIBRANT trial for verekitug in chronic rhinosinusitis with nasal polyps, meeting primary and key secondary endpoints with a favorable safety profile.

Upstream Bio announced its second quarter 2025 financial results and provided updates on its clinical development programs for verekitug in severe respiratory diseases.

Upstream Bio, Inc. announced that its stockholders approved the election of two Class I directors and ratified PricewaterhouseCoopers LLP as its independent auditor for the 2025 fiscal year at the recent Annual Meeting.

Upstream Bio reports its Q1 2025 financial results, highlighting progress in its verekitug clinical programs and accelerating guidance on key milestones.

Upstream Bio announces completion of Phase 2 clinical trial enrollment for verekitug in CRSwNP and reports financial results for Q4 and full year 2024, highlighting a strong cash position extending through 2027.

Upstream Bio announced its Q3 2024 financial results, highlighted by the advancement of its Phase 2 clinical trials for verekitug and the completion of an upsized IPO, extending its operational runway through 2027.

Upstream Bio has officially filed its third amended and restated certificate of incorporation and second amended and restated bylaws, completing key steps following its initial public offering.